NeoGenomics, Inc. - Common Stock (NEO)

Competitors to NeoGenomics, Inc. - Common Stock (NEO)

Exact Sciences Corporation 

Exact Sciences primarily focuses on molecular diagnostics and has a strong presence in cancer screening and detection, particularly for colorectal cancer. While NeoGenomics specializes more in diagnostic testing for a range of cancers, the two companies compete for clients in oncological testing services. Exact Sciences holds a competitive advantage in specific niches due to its targeted product offerings and established relationships within the healthcare system, although NeoGenomics has a broader scope in genomics.

Guardant Health, Inc. 

Guardant Health specializes in non-invasive cancer detection through liquid biopsy technology, positioning it as a competitor to NeoGenomics, which offers a range of genomic tests for cancer. While both companies target the oncology market, Guardant focuses heavily on advanced genomic profiling and personalized medicine. Guardant Health has carved out a substantial market for itself due to its innovation in the field, providing it with a competitive edge, particularly in the realm of early detection and precision oncology.

LabCorp 

LabCorp offers a wide variety of laboratory and diagnostic services, competing directly with NeoGenomics in the area of genetic and molecular testing. LabCorp's extensive infrastructure and established presence in the laboratory services market allow it to provide testing solutions at a large scale. However, NeoGenomics specializes specifically in cancer testing and may have more focused expertise in this area, which could enhance its service offerings relative to LabCorp's broader testing slate.

Myriad Genetics, Inc. 

Myriad Genetics focuses on genetic testing, particularly in the areas of hereditary cancers, and competes with NeoGenomics in the oncology testing space. Both companies provide valuable insights that can inform treatment options for patients based on genetic markers. Myriad has established a robust reputation in the genetic testing market, especially for BRCA testing, providing it a competitive advantage. However, NeoGenomics' broader array of genomic testing services and partnership initiatives may help it maintain a strong position in the market.

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific is a major player in the diagnostics and life sciences sector, offering a broad portfolio of products and services that overlap with NeoGenomics' offerings, particularly in genomic testing and laboratory services. Both companies provide comprehensive testing solutions, but Thermo Fisher benefits from its size, extensive research capabilities, and diverse product range, allowing it to cater to a wider customer base across different sectors, including clinical research and pharmaceutical development.